Metropolis (METROPOLIS) | Financial Analysis & Statements
Metropolis Healthcare Ltd. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
4.1B
Gross Profit
3.2B
78.49%
Operating Income
629.7M
15.51%
Net Income
420.9M
10.37%
EPS (Diluted)
₹1.99
Balance Sheet Metrics
Total Assets
18.7B
Total Liabilities
5.3B
Shareholders Equity
13.3B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
491.2M
Free Cash Flow
320.7M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Metropolis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 13.3B | 12.1B | 11.5B | 12.3B | 10.0B |
| Cost of Goods Sold | 2.8B | 2.6B | 2.6B | 2.9B | 2.6B |
| Gross Profit | 10.5B | 9.5B | 8.8B | 9.4B | 7.4B |
| Gross Margin % | 78.7% | 78.4% | 77.0% | 76.6% | 73.9% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 1.9B | 1.7B | 1.6B | 1.7B | 971.5M |
| Other Operating Expenses | 1.0B | 1.0B | 802.7M | 753.3M | 859.6M |
| Total Operating Expenses | 2.9B | 2.7B | 2.4B | 2.5B | 1.8B |
| Operating Income | 2.1B | 2.0B | 2.1B | 2.9B | 2.5B |
| Operating Margin % | 15.5% | 16.8% | 18.2% | 23.5% | 24.7% |
| Non-Operating Items | |||||
| Interest Income | 35.1M | 32.6M | 57.1M | 111.5M | 93.0M |
| Interest Expense | 185.7M | 225.4M | 268.0M | 197.4M | 77.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.9B | 1.7B | 1.9B | 2.9B | 2.4B |
| Income Tax | 453.4M | 462.3M | 441.1M | 786.6M | 609.7M |
| Effective Tax Rate % | 23.8% | 26.5% | 23.5% | 26.8% | 25.0% |
| Net Income | 1.5B | 1.3B | 1.4B | 2.1B | 1.8B |
| Net Margin % | 10.9% | 10.6% | 12.5% | 17.5% | 18.4% |
| Key Metrics | |||||
| EBITDA | 3.1B | 2.9B | 3.0B | 3.6B | 3.0B |
| EPS (Basic) | ₹7.07 | ₹24.95 | ₹27.91 | ₹41.87 | ₹35.97 |
| EPS (Diluted) | ₹7.04 | ₹24.87 | ₹27.81 | ₹41.66 | ₹35.79 |
| Basic Shares Outstanding | 205010600 | 51219781 | 51196399 | 51156132 | 50903685 |
| Diluted Shares Outstanding | 205010600 | 51219781 | 51196399 | 51156132 | 50903685 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Metropolis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 394.8M | 626.2M | 688.3M | 659.8M | 3.9B |
| Short-term Investments | 787.8M | 616.7M | 252.4M | 1.1B | 338.4M |
| Accounts Receivable | 1.5B | 1.3B | 1.2B | 1.4B | 1.2B |
| Inventory | 478.4M | 386.9M | 445.9M | 511.1M | 405.5M |
| Other Current Assets | 246.1M | 202.8M | 159.4M | 143.1M | -4.6M |
| Total Current Assets | 3.5B | 3.2B | 3.0B | 3.9B | 6.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.8B | 2.6B | 2.5B | 1.9B | 1.7B |
| Goodwill | 16.8B | 13.0B | 12.8B | 12.7B | 2.2B |
| Intangible Assets | 5.0B | 3.9B | 3.7B | 3.6B | 345.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -12.0K | -1.0K | -347 | -2.0K | 6.7M |
| Total Non-Current Assets | 15.2B | 12.4B | 12.0B | 11.4B | 4.0B |
| Total Assets | 18.7B | 15.6B | 15.0B | 15.3B | 10.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.3B | 994.4M | 940.8M | 1.0B | 1.1B |
| Short-term Debt | 920.7M | 780.0M | 1.1B | 1.4B | 333.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | 240.1M | -1.0K | 53.5M | 146.2M |
| Total Current Liabilities | 2.9B | 2.5B | 2.6B | 3.0B | 2.0B |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.1B | 1.2B | 1.5B | 2.4B | 789.3M |
| Deferred Tax Liabilities | 995.1M | 750.5M | 782.4M | 866.7M | 41.6M |
| Other Non-Current Liabilities | - | - | 1.0K | - | - |
| Total Non-Current Liabilities | 2.4B | 2.1B | 2.5B | 3.4B | 923.9M |
| Total Liabilities | 5.3B | 4.6B | 5.1B | 6.4B | 3.0B |
| Equity | |||||
| Common Stock | 103.6M | 102.5M | 102.4M | 102.3M | 102.2M |
| Retained Earnings | 10.3B | 8.9B | 7.8B | 6.8B | 5.1B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 13.3B | 11.0B | 9.9B | 8.9B | 7.1B |
| Key Metrics | |||||
| Total Debt | 2.0B | 2.0B | 2.7B | 3.8B | 1.1B |
| Working Capital | 516.1M | 699.6M | 377.6M | 915.7M | 4.0B |
Balance Sheet Composition
Metropolis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.9B | 1.7B | 1.9B | 2.9B | 2.4B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 70.1M | 14.2M | 2.9M | 68.6M | 77.9M |
| Working Capital Changes | -228.7M | -17.0M | 125.9M | -32.2M | -391.8M |
| Operating Cash Flow | 1.9B | 1.9B | 2.2B | 3.0B | 2.1B |
| Investing Activities | |||||
| Capital Expenditures | -414.1M | -637.6M | -524.8M | -306.6M | -281.9M |
| Acquisitions | -1.3B | -6.5M | -4.5M | -6.4B | -53.9M |
| Investment Purchases | -5.3B | -1.6B | -2.6B | -800.4M | 0 |
| Investment Sales | 5.3B | 1.3B | 3.5B | 0 | 848.5M |
| Investing Cash Flow | -1.8B | -915.8M | 398.4M | -7.6B | 458.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -205.0M | -409.7M | -409.4M | -408.9M |
| Debt Issuance | - | - | 0 | 6.0B | 0 |
| Debt Repayment | -7.5M | -790.5M | -1.8B | -3.4B | -351.0K |
| Financing Cash Flow | -7.4M | -995.4M | -2.2B | -1.2B | -74.7M |
| Free Cash Flow | 1.9B | 2.0B | 1.9B | 2.2B | 2.2B |
| Net Change in Cash | 118.9M | 25.6M | 416.6M | -5.7B | 2.5B |
Cash Flow Trend
Metropolis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
58.44
Forward P/E
38.75
Price to Book
6.85
Price to Sales
6.26
PEG Ratio
-0.87
Profitability Ratios
Profit Margin
10.74%
Operating Margin
15.51%
Return on Equity
10.86%
Return on Assets
7.76%
Financial Health
Current Ratio
1.18
Debt to Equity
13.92
Beta
0.07
Per Share Data
EPS (TTM)
₹8.10
Book Value per Share
₹69.15
Revenue per Share
₹75.79
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| METROPOLIS | 97.9B | 58.44 | 6.85 | 10.86% | 10.74% | 13.92 |
| Dr. Lal PathLabs | 238.9B | 46.16 | 10.20 | 22.08% | 19.84% | 6.44 |
| Sai Life Sciences | 217.1B | 64.75 | 9.48 | 7.99% | 15.34% | 18.40 |
| Syngene | 169.3B | 48.19 | 3.57 | 10.50% | 9.47% | 12.28 |
| Vijaya Diagnostic | 109.6B | 67.41 | 12.37 | 17.90% | 20.73% | 42.22 |
| Thyrocare | 62.9B | 45.42 | 11.76 | 16.73% | 17.35% | 4.62 |
Financial data is updated regularly. All figures are in the company's reporting currency.





